WOMEN'S HEALTH: U.S. MARKETS FOR OSTEOPOROSIS MANAGEMENT PRODUCTS
129 Pages | 30 Exhibits | 2008 Analysis | Forecasts Through 2010
In 2007, the United States (U.S.) market for osteoporosis management products totaled approximately $7.6 billion.
Sales of these products are expected to increase at a compound annual rate of 6.6%, reaching an estimated $9.3
billion in the year 2010.
This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. osteoporosis management products market. According to the first-ever U.S. Surgeon General's report on the nation's bone health, by the year 2020 one out of two Americans over the age of 50 will be at risk for fractures from osteoporosis. Currently, approximately 10 million people in the U.S. are estimated to have osteoporosis, and another 34 million are believed to have low bone mass, placing them at risk for developing osteoporosis.
Products for the diagnosis and treatment of osteoporosis that are covered in this report include biochemical markers, bone densitometry systems, and hormone replacement and osteoporosis drugs. These include antiresorptive drugs such as bisphosphonates, calcitonins, estrogen, and selective estrogen receptor modulators; bone-forming drugs such as parathyroid hormone and sodium fluoride; combination drugs; and treatments such as cathepsin K inhibitors, gene therapy, monoclonal antibodies, selective androgen receptor modulators, and statin drugs.
This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. osteoporosis management products market. According to the first-ever U.S. Surgeon General's report on the nation's bone health, by the year 2020 one out of two Americans over the age of 50 will be at risk for fractures from osteoporosis. Currently, approximately 10 million people in the U.S. are estimated to have osteoporosis, and another 34 million are believed to have low bone mass, placing them at risk for developing osteoporosis.
Products for the diagnosis and treatment of osteoporosis that are covered in this report include biochemical markers, bone densitometry systems, and hormone replacement and osteoporosis drugs. These include antiresorptive drugs such as bisphosphonates, calcitonins, estrogen, and selective estrogen receptor modulators; bone-forming drugs such as parathyroid hormone and sodium fluoride; combination drugs; and treatments such as cathepsin K inhibitors, gene therapy, monoclonal antibodies, selective androgen receptor modulators, and statin drugs.
EXECUTIVE SUMMARY i. Osteoporosis Incidence and Prevalence ii. Osteoporosis Diagnosis and Management a. Bone Densitometry b. Biochemical Markers c. Osteoporosis Treatments iii. Market Analysis a. Bone Densitometry Systems b. Biochemical Markers c. Hormone Replacement Therapy and Osteoporosis Drugs i. Hormone Replacement Therapy Drugs ii. Osteoporosis Drugs iv. Methodology Exhibit ES-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2005-2010 Exhibit ES-3: Total Bone Densitometry Systems, Market Forecast, 2005-2010 Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010 Exhibit ES-5: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category Exhibit ES-6: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010 Exhibit ES-7: Osteoporosis Drugs, Market Forecast, 2005-2010 Exhibit ES-8: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010 1. OSTEOPOROSIS MANAGEMENT PRODUCTS MARKET 1.1 Overview of Osteoporosis 1.1.1 Incidence, Prevalence, and Cost 1.1.2 Types of Osteoporosis 1.1.3 Risk Factors 1.2 Diagnosis 1.2.1 Bone Densitometry 1.2.1.1 Products, by Application 1.2.1.1.1 Hospital-Based Densitometry Systems 1.2.1.1.2 Office-Based Densitometry Systems 1.2.1.1.3 Software-Based Systems 1.2.1.2 Products and Suppliers 1.2.1.2.1 CooperSurgical/The Cooper Companies 1.2.1.2.2 GE Healthcare/General Electric Company 1.2.1.2.3 Hologic 1.2.1.3 Market Analysis 1.2.1.4 Competitive Analysis 1.2.2 Biochemical Markers 1.2.2.1 Types 1.2.2.2 Applications 1.2.2.3 Products and Suppliers 1.2.2.3.1 Beckman Coulter 1.2.2.3.2 Roche Diagnostics/F. Hoffmann- La Roche/Roche Holding 1.2.2.3.3 Inverness Medical Innovations 1.2.2.3.4 Orion Diagnostica Oy/Orion Group 1.2.2.3.5 Quidel 1.2.2.4 Market Analysis 1.2.2.5 Competitive Analysis 1.3 Treatment 1.3.1 Antiresorptive Drugs 1.3.1.1 Estrogen 1.3.1.2 Selective Estrogen Receptor Modulators 1.3.1.2.1 EVISTA 1.3.1.3 Calcitonins 1.3.1.4 Bisphosphonates 1.3.1.4.1 Actonel 1.3.1.4.2 Boniva 1.3.1.4.3 FOSAMAX 1.3.2 Bone-Forming Drugs 1.3.2.1 Sodium Fluoride 1.3.2.2 Parathyroid Hormone 1.3.2.2.1 FORTEO 1.3.3 Dual-Acting Drug 1.3.4 Other Treatments 1.3.4.1 Monoclonal Antibodies 1.3.4.2 Cathepsin K Inhibitors 1.3.4.3 Gene Therapy 1.3.4.4 Statin Drugs 1.3.4.5 Selective Androgen Receptor Modulators 1.3.5 Market Analysis 1.3.5.1 Hormone Replacement Therapy Drugs 1.3.5.2 Osteoporosis Drugs 1.3.6 Competitive Analysis 1.3.7 Combined Market Analysis Exhibit 1-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site Exhibit 1-2: Prevalence of Osteoporosis and Low Bone Mass in Men and Women Age 50 and Older, by Ethnicity Exhibit 1-3: Types of Osteoporosis Exhibit 1-4: Leading Risk Factors for Osteoporosis Exhibit 1-5: Comparison of Bone Densitometry and Osteoporosis Biochemical Marker Screenings Exhibit 1-6: Imaging Technologies Used to Diagnose Osteoporosis Exhibit 1-7: 2008, Selected Bone Densitometry Systems Exhibit 1-8: Bone Densitometry Hospital Systems, Market Forecast, 2005-2010 Exhibit 1-9: Bone Densitometry Office Systems, Market Forecast, 2005-2010 Exhibit 1-10: Total Bone Densitometry Systems, Market Forecast, 2005-2010 Exhibit 1-11: 2007, Bone Densitometry Systems Market, Share by Supplier Exhibit 1-12: Comparison of Bone Remodeling Biochemical Markers Exhibit 1-13: 2008, Selected Bone Remodeling Biochemical Marker Tests Exhibit 1-14: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010 Exhibit 1-15: 2007, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier Exhibit 1-16: 2008, Selected Current and Emerging Pharmaceutical Treatments for Osteoporosis Exhibit 1-17: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010 Exhibit 1-18: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category Exhibit 1-19: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010 Exhibit 1-20: Osteoporosis Drugs, Market Forecast, 2005-2010 Exhibit 1-21: 2007, Hormone Replacement Therapy and Osteoporosis Drugs Market, Share by Supplier Exhibit 1-22: Osteoporosis Management Products, Combined Market Forecast, 2005-2010 2. COMPANY PROFILES 2.1 The Cooper Companies, Inc. 2.2 General Electric Company 2.3 Hologic, Inc. 2.4 Inverness Medical Innovations, Inc. 2.5 Eli Lilly and Company 2.6 Merck & Company, Inc. 2.7 Novartis AG 2.8 Procter & Gamble Company 2.9 Quidel Corporation 2.10 Roche Holding AG 2.11 Wyeth APPENDIX: COMPANY LISTING
The following companies are covered in this report:
- Abbott Laboratories, Inc.
- AstraZeneca PLC
- Bayer
- Beckman Coulter, Inc.
- Chiron Corporation
- Novartis Vaccines and Diagnostics, Inc.
- Novartis AG
- CompuMed, Inc.
- CooperSurgical, Inc./ The Cooper Companies, Inc.
- EffRx, Inc.
- Eli Lilly and Company
- Emisphere Technologies, Inc.
- FUJIFILM Medical Systems USA, Inc./FUJIFILM Corporation
- Galapagos NV
- GE Healthcare/ General Electric Company
- Genentech, Inc.
- GlaxoSmithKline PLC
- GTx, Inc.
- F. Hofmann-La Roche LTD/ Roche Holding LTD
- Hologic, Inc.
- Human Genome Sciences, Inc.
- Inverness Medical Innovations, Inc.
- Ligand Pharmaceuticals, Inc.
- Lone Oak Medical Technologies LLC
- Merck & Company, Inc.
- Nastech Pharmaceutical Company, Inc.
- Novartis AG
- Noven Pharmaceuticals, Inc.
- Novogen LTD
- Novogyne Pharmaceuticals
- NPS Pharmaceuticals, Inc.
- Nycomed International Management GmbH
- Orion Diagnostica Oy/ Orion Corporation
- Oscient Pharmaceuticals Corporation
- Pfizer, Inc.
- Procter & Gamble Company
- ProStrakan Group PLC
- Quidel Corporation
- Roche Diagnostics Corporation/ F. Hoffmann-La Roche LTD/ Roche Holding LTD
- sanofi-aventis
- Sectra AB
- SERVIER SA
- Takeda Pharmaceutical Company LTD
- TAP Pharmaceutical Products, Inc.
- Unigene Laboratories, Inc.
- Upsher-Smith Laboratories, Inc.
- Warner Chilcott LTD
Request Sample

A Single License allows for one person to access the report. A Corporate License allows for multiple individuals within a company to access the report.